Krishzyme Recombinant Carboxypeptidase B

Krishzyme Recombinant Carboxypeptidase B, also known as peptidyl-L-lysine (L-arginine) hydrolase; arginase, is a digestive enzyme that plays a crucial role in biological systems. It primarily participates in the digestion process by specifically hydrolyzing the basic amino acid residues at the C-terminal end of proteins. Recombinant Carboxypeptidase B degrades peptide chains from the C-terminal end, releasing free amino acids one by one. It specifically hydrolyzes peptide bonds of lysine, arginine, or histidine (to a lesser extent), which are all basic and positively charged amino acids. Recombinant Carboxypeptidase B is a metalloproteinase with a zinc ion in its active centre, which is essential for its catalytic activity. The zinc ion is typically located in the enzyme`s active centre and participates in substrate binding and catalytic reactions. Krishzyme Recombinant Carboxypeptidase B is produced by recombinant E. coli expression, with an amino acid sequence identical to that of pancreatic carboxypeptidase B. It possesses the same enzymatic properties as animal-derived carboxypeptidase B and can be used as a substitute for animal-derived carboxypeptidase B in various biotechnological processes. Recombinant Carboxypeptidase B has multiple important applications in the biotechnology field, particularly in protein engineering, drug development, and biopharmaceuticals. Some specific applications of carboxypeptidase B are as follows: 1. Determination of C-terminal amino acids of proteins 2. Production and processing of biopharmaceuticals 3. Protein Function Research 4. Protein Modification and Labelling 5. Preparation of Biological Materials Krishzyme Recombinant Carboxypeptidase B maintains the same specificity and activity as animal-derived carboxypeptidase B, with a specific activity over 170 U/mg. It can replace traditional carboxypeptidase B extracted from animal pancreas for use in biotechnological processes such as drug synthesis and biological sample processing. Recombinant carboxypeptidase B produced through this technology is free from trypsin and other contaminating enzymes and protease inhibitors, offering higher specificity and avoiding potential cross-reactions and inhibitions.